Amneal Pharmaceuticals (AMRX) Net Income towards Common Stockholders (2018 - 2026)

Amneal Pharmaceuticals has reported Net Income towards Common Stockholders for 9 years, with the latest figure at $69.6 million in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 95.49% year-over-year to $69.6 million in Q2 2026; TTM through Jun 2026 was $215.3 million, a 320.19% increase from a year earlier, with the FY2025 full-year figure at $127.9 million, up 209.45% from the prior year.
• Net Income towards Common Stockholders was $69.6 million for Q2 2026 at Amneal Pharmaceuticals, down from $78.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $78.0 million in Q1 2026, with the low at -$120.8 million in Q2 2022.
• Average Net Income towards Common Stockholders over 5 years is -$683777.8, with a median of $10.7 million recorded in 2023.
• The largest YoY upside for Net Income towards Common Stockholders was 460.06% in 2023 against a maximum downside of 2176.69% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at -$4.3 million in 2022, then plunged by 2176.69% to -$98.6 million in 2023, then surged by 78.97% to -$20.7 million in 2024, then jumped by 339.0% to $49.6 million in 2025, then surged by 40.43% to $69.6 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $69.6 million (Q2 2026), $78.0 million (Q1 2026), and $49.6 million (Q4 2025), per Business Quant data.